БИОЛОГИЧЕСКИЙ СПЕКТР АКТИВНОСТИ АЗАГЕТЕРОЦИКЛИЧЕСКИХ СОЕДИНЕНИЙ

2021

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.26577/eb.2021.v87.i2.12
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

The demand for immunostimulants and immunomodulators in the pharmaceutical market is wide. They are used in the treatment of congenital, acquired immunodeficiency states, in the treatment of cancer patients, in the treatment of patients living in ecologically unfavorable regions of countries, etc. And modern immunopharmacology faces a global challenge in the development of targeted immunostimulants. Thus, the presented spectrum of immunostimulating drugs shows that each group of immunostimulants has a certain spectrum of side effects and synthetic drugs are a more promising group. Therefore, the screening of new promising immunostimulants of targeted synthetics is justified. To study the hemogram of peripheral blood, we used 48 adult female albino laboratory rats, and phenotyping of lymphocytes was carried out by the conventional method of indirect fluorescence using monoclonal antibodies. As a result, the blood leukogram changed towards the development of leukopenic processes. Compound 2 exhibited comparatively low lymphopoiesis-stimulating activity among the compounds studied. Compound 3 showed comparatively high lymphopoiesis-stimulating activity in the series of compounds 1, 2, and 3. The erythropoiesis-stimulating and thrombocytopoiesis-stimulating activity of compounds 1 and 3 was at the level of the reference drug methyluracil.